다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
Regulus Therapeutics Inc (RGLS)
Regulus Therapeutics Inc (RGLS) 뉴스

RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:RGLS

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/18	06:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/18	05:44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/18	05:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/18	05:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/18	05:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/16	21:00	PR Newswire (US)	Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/10	05:54	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/10	05:27	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/10	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/10	05:05	PR Newswire (US)	Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/06	21:00	PR Newswire (US)	Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/04/30	21:00	PR Newswire (US)	Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/03/22	05:05	PR Newswire (US)	Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/03/12	19:32	PR Newswire (US)	Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/03/12	19:30	PR Newswire (US)	Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/19	10:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/19	10:23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/18	07:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/18	07:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/13	06:11	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/10	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/03	06:05	PR Newswire (US)	Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/12/28	06:16	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/22	22:00	PR Newswire (US)	Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/10	06:39	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/10	06:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/10	06:05	PR Newswire (US)	Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/02	21:00	PR Newswire (US)	Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/10/19	21:00	PR Newswire (US)	Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/09/20	20:00	PR Newswire (US)	Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc

검색 관련기사 보기:NASDAQ:RGLS

1 2 3 4 5 6 7 8 9 10 다음 >>

Lehman Abs 8.20 Moto

IT0005590788 20241202 31

Ubs Bbg Jt 1-3 Ucits Etf...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관